Immutep picks up more funds for LAG-3 oncology and autoimmune studies
Immutep has raised about $53 million to bankroll its LAG-3 drugs across oncology and autoimmune diseases, giving it a cash runway to the first quarter of 2026.
The funds will bankroll a registrational-directed Phase III trial in lung cancer, late-stage studies in head and neck cancer, and trial readouts in metastatic and triple-negative breast cancer, chair Russell Howard said in a statement. The capital could also support clinical entry on the autoimmune front, the chair added.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.